Literature DB >> 6497947

Does nifedipine suppress atherogenesis in WHHL rabbits?

J L Van Niekerk, T Hendriks, H H De Boer, A Van 't Laar.   

Abstract

The effects of the calcium antagonist, nifedipine, on atherogenesis were investigated in WHHL rabbits, a unique animal model for human familial hypercholesterolemia. Nifedipine, in a daily dose of 40 mg, was fed orally to 9 rabbits over a period of 26 weeks, resulting in serum concentrations of between 740 and 1370 ng/ml. Rabbits were killed at an age of 40 weeks and atherosclerotic plaque formation in various aortic segments was quantified. Atherosclerosis was most pronounced in the aortic arch and the thoracic aorta, plaques covering, respectively, 59 +/- 17% and 17 +/- 9% of total vessel area. These results are similar to those observed in a control group, which received the same diet and no nifedipine and displayed lesions on 62 +/- 19% and 21 +/- 13% of total area of aortic arch and thoracic aorta, respectively. Although variations in plaque area between WHHL rabbits are large and thus preclude the observation of small effects, the efficacy of nifedipine as an anti-atherogenic agent in rabbits with hereditary hypercholesterolemia appears questionable.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6497947     DOI: 10.1016/0021-9150(84)90109-6

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  Watanabe heritable hyperlipidemic rabbits. Familial hypercholesterolemia.

Authors:  J B Atkinson; L L Swift; R Virmani
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

2.  Quantitative analysis of antiatherosclerotic effect of nifedipine in cholesterol-fed rabbits.

Authors:  Y Ohta; N Higuchi; S Emura; T Takashima; K Oogushi; H Kato; K Ohmori; T Sunaga
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists?

Authors:  W Schneider; G Kober; P Roebruck; H Noack; M Alle; G Cieslinski; N Reifart; M Kaltenbach
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110.

Authors:  D A Handley; R G Van Valen; M K Melden; R N Saunders
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

Review 5.  Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation.

Authors:  Paraskevi Tziortzouda; Ludo Van Den Bosch; Frank Hirth
Journal:  Nat Rev Neurosci       Date:  2021-03-02       Impact factor: 34.870

Review 6.  ACE-inhibitors and atherosclerosis.

Authors:  E Ambrosioni; S Bacchelli; D Degli Esposti; C Borghi
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

7.  International nifedipine trial on antiatherosclerotic therapy (INTACT).

Authors:  P R Lichtlen; U Nellessen; W Rafflenbeul; S Jost; H Hecker
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

8.  Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells. A possible mechanism for its antiatherogenic effect.

Authors:  O R Etingin; D P Hajjar
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

Review 9.  Roles of the WHHL rabbit in translational research on hypercholesterolemia and cardiovascular diseases.

Authors:  Tsutomu Kobayashi; Takashi Ito; Masashi Shiomi
Journal:  J Biomed Biotechnol       Date:  2011-04-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.